Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ultragenyx Pharmaceutical's total inventories for the quarter that ended in Mar. 2026 was MXN992 Mil. Ultragenyx Pharmaceutical's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was MXN964 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ultragenyx Pharmaceutical's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was MXN-183.55.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ultragenyx Pharmaceutical's Days Inventory for the
three
months ended in Mar. 2026 was 162.61.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Ultragenyx Pharmaceutical's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.56.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ultragenyx Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.39.
Ultragenyx Pharmaceutical (MEX:RARE) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Ultragenyx Pharmaceutical's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ultragenyx Pharmaceutical's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Ultragenyx Pharmaceutical Total Inventories Related Terms
Ultragenyx Pharmaceutical Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ultragenyx Pharmaceutical Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Ultragenyx Pharmaceutical (MEX:RARE) has a Total Inventories of MXN992 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Total Inventories too high?
Ultragenyx Pharmaceutical's current Total Inventories is MXN992 Mil. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Total Inventories compare to VERA and IRON?
Ultragenyx Pharmaceutical's Total Inventories of MXN992 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Total Inventories is MXN992 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Ultragenyx Pharmaceutical (MEX:RARE) has a current Total Inventories of MXN992 Mil. The stock's GF Value™ is MXN1,699.44, compared to a current price of MXN1,150.56 — trading 32.3% below its estimated fair value. The current Total Inventories is MXN992 Mil. Ultragenyx Pharmaceutical's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Total Inventories is MXN992 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued.
The current stock price of MXN1,150.56 is trading 32.3% below its estimated GF Value™ of MXN1,699.44.
Key valuation signals for MEX:RARE:
Total Inventories: MXN992 Mil
GF Value™: MXN1,699.44 vs. price of MXN1,150.56 (32.3% below fair value)
No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
70GF Score
Get the complete analysis for MEX:RARE
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RARE has been successfully added to your 
